Insmed saw the highest growth of 1.99% in patent filings in April and 2.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.99% and grants by 1.32%. GlobalData’s DataBook provides a comprehensive analysis of Insmed‘s patent filings and grants. Buy the databook here.
Insmed has been focused on protecting inventions in Japan(JP) with six publications in Q2 2024
The Japan(JP) Patent Office dominates the patent filings and grants with nearly 33% filings and 12% grants. The Japan(JP), European Patent Office(EPO), United States(US), and South Korea(KR) patent Office are among the top ten patent offices where Insmed is filings its patents. Among the top granted patent authorities, Insmed has 38% of its grants in South Korea(KR), 25% in United States(US) and 12% in Japan(JP).
Zambon Co could be the strongest competitor for Insmed
Patents related to rare diseases and nanomedicine lead Insmed's portfolio
Insmed has the highest number of patents in rare diseases followed by, nanomedicine and climate change. For rare diseases, nearly 60% of patents were filed and 20% of patents were granted in Q2 2024.
Pulmonary hypertension related patents lead Insmed portfolio followed by pulmonary arterial hypertension, and lung disease
Insmed has highest number of patents in pulmonary hypertension followed by pulmonary arterial hypertension, lung disease, anesthesia and respiratory devices, and hypertension.
For comprehensive analysis of Insmed's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.